Menu
Back to Journals » OncoTargets and Therapy » Volume 5 » default
OncoTargets and Therapy
ISSN: 1178-6930
- View all (6340)
- Volume 16, 2023 (49)
- Volume 15, 2022 (191)
- Volume 14, 2021 (525)
- Volume 13, 2020 (1171)
- Volume 12, 2019 (1075)
- Volume 11, 2018 (882)
- Volume 10, 2017 (615)
- Volume 9, 2016 (802)
- Volume 8, 2015 (439)
- Volume 7, 2014 (253)
- Volume 6, 2013 (208)
- Volume 5, 2012 (54)
- Volume 4, 2011 (19)
- Volume 3, 2010 (22)
- Volume 2, 2009 (25)
- Volume 1, 2008 (10)
Archive: Volume 5, 2012
Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study
Huang L, Li GM, Zhu JY, Li Z, Li T, Leng XS
OncoTargets and Therapy 2012, 5:457-462
Published Date: 20 December 2012
Endoscopy-verified occult subependymal dissemination of glioblastoma and brain metastasis undetected by MRI: prognostic significance
Iacoangeli M, Di Rienzo A, Colasanti R, Zizzi A, Gladi M, Alvaro L, Nocchi N, Di Somma LG, Scarpelli M, Scerrati M
OncoTargets and Therapy 2012, 5:449-456
Published Date: 13 December 2012
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, Xu J, Zhu G, Zhang L
OncoTargets and Therapy 2012, 5:439-447
Published Date: 12 December 2012
Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions
Karanikas M, Machairiotis N, Zarogoulidis P, Stylianaki A, Courcoutsakis N, Mitrakas A, Touzopoulos P, Lyratzopoulos N, Kouklakis G, Spanoudakis M, Polychronidis A
OncoTargets and Therapy 2012, 5:433-438
Published Date: 12 December 2012
Impact of CHK2-small interfering RNA on CpG ODN7909-enhanced radiosensitivity in lung cancer A549 cells
Chen W, Liu XQ, Qiao TK, Yuan SJ
OncoTargets and Therapy 2012, 5:425-431
Published Date: 3 December 2012
Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma
Cangemi G, Reggiardo G, Barco S, Barbagallo L, Conte M, D'Angelo P, Bianchi M, Favre C, Galleni B, Melioli G, Haupt R, Garaventa A, Corrias MV
OncoTargets and Therapy 2012, 5:417-423
Published Date: 30 November 2012
Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
Fernandes I, Pacheco TR, Costa A, Santos AC, Fernandes AR, Santos M, Oliveira AG, Casimiro S, Quintela A, Fernandes A, Ramos M, Costa L
OncoTargets and Therapy 2012, 5:409-416
Published Date: 28 November 2012
Abnormal expression of PER1 circadian-clock gene in oral squamous cell carcinoma
Chen R, Yang K, Zhao NB, Zhao D, Chen D, Zhao CR, Tang H
OncoTargets and Therapy 2012, 5:403-407
Published Date: 27 November 2012
β-blockers: a novel class of antitumor agents
Ji Y, Chen S, Xiao X, Zheng S, Li K
OncoTargets and Therapy 2012, 5:391-401
Published Date: 26 November 2012
The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis
Tasci C, Ozkaya S, Ozkara B, Tozkoparan E, Ozkan M, Karadurmus N, Serdar M, Balkan A, Bilgic H
OncoTargets and Therapy 2012, 5:385-390
Published Date: 22 November 2012
Cancer stem cells in head and neck cancer
Allegra E, Trapasso S
OncoTargets and Therapy 2012, 5:375-383
Published Date: 21 November 2012
Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
Hountis P, Foukas PG, Matthaios D, Kefala M, Chelis L, Pantelidaki A, Panayiotides IG, Karakitsos P, Kakolyris S
OncoTargets and Therapy 2012, 5:363-373
Published Date: 21 November 2012
Rare synchronous association of vestibular schwannoma and indolent insular oligodendroglioma in a patient without neurofibromatosis: controversial issue of timing for surgical treatment of asymptomatic low-grade gliomas
Iacoangeli M, Di Rienzo A, Colasanti R, Alvaro L, Nocchi N, Polonara G, Di Somma LG, Zizzi A, Scarpelli M, Scerrati M
OncoTargets and Therapy 2012, 5:357-361
Published Date: 19 November 2012
The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution
Zhang J, Huang Y, Li X, Guo Y, Zhao Y, Xue C, Hu Z, Zhang L, Zhao H
OncoTargets and Therapy 2012, 5:349-355
Published Date: 15 November 2012
Tumor necrosis factor signaling is implicated in intestinal mucosal injury of cancer cachexic mice
Jia Y, Tian W, Cui B
OncoTargets and Therapy 2012, 5:343-348
Published Date: 12 November 2012
A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro
Sun QL, Zhang XG, Xing QT, Ding P, Feng JB, Wu XP, Wang ZM
OncoTargets and Therapy 2012, 5:335-342
Published Date: 9 November 2012
Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance
Chen HF, Wu TQ, Li ZY, Shen HS, Tang JQ, Fu WJ, Yuan ZG, Hou J
OncoTargets and Therapy 2012, 5:329-334
Published Date: 7 November 2012
Targeted treatments for cervical cancer: a review
Peralta-Zaragoza O, Bermúdez-Morales VH, Pérez-Plasencia C, Salazar-León J, Gómez-Cerón C, Madrid-Marina V
OncoTargets and Therapy 2012, 5:315-328
Published Date: 2 November 2012
γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer
Matthaios D, Foukas PG, Kefala M, Hountis P, Trypsianis G, Panayiotides IG, Chatzaki E, Pantelidaki E, Bouros D, Karakitsos P, Kakolyris S
OncoTargets and Therapy 2012, 5:309-314
Published Date: 30 October 2012
Current and emerging treatment options for nasopharyngeal carcinoma
Spratt DE, Lee N
OncoTargets and Therapy 2012, 5:297-308
Published Date: 23 October 2012
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C
OncoTargets and Therapy 2012, 5:287-296
Published Date: 23 October 2012
Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells
Li Y, Dai C, Li J, Wang W, Song G
OncoTargets and Therapy 2012, 5:279-286
Published Date: 17 October 2012
Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901
Dan L, Jian D, Na L, Xiaozhong W
OncoTargets and Therapy 2012, 5:271-277
Published Date: 23 October 2012
Research progress on criteria for discontinuation of EGFR inhibitor therapy
Zhuang HQ, Yuan ZY, Wang J, Wang P, Zhao LJ, Zhang BL
OncoTargets and Therapy 2012, 5:263-270
Published Date: 15 October 2012
Clinicopathological and prognostic significance of epithelial mesenchymal transition-related protein expression in intrahepatic cholangiocarcinoma
Yao X, Wang X, Wang Z, Dai L, Zhang G, Yan Q, Zhou W
OncoTargets and Therapy 2012, 5:255-261
Published Date: 12 October 2012
Helical tomotherapy provides efficacy similar to that of intensity-modulated radiation therapy with dosimetric benefits for endometrial carcinoma
Hsieh CH, Shueng PW, Hsiao SM, Wei MC, Wu WY, Sun HD, Tien HJ, Wang LY, Hsieh YP
OncoTargets and Therapy 2012, 5:245-253
Published Date: 1 October 2012
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
Fostier K, De Becker A, Schots R
OncoTargets and Therapy 2012, 5:237-244
Published Date: 28 September 2012
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival
Zarogoulidis P, Mavroudi M, Porpodis K, Domvri K, Sakkas A, Machairiotis N, Stylianaki A, Tsiotsios A, Courcoutsakis N, Zarogoulidis K
OncoTargets and Therapy 2012, 5:231-236
Published Date: 27 September 2012
Denosumab: a new option in the treatment of bone metastases from urological cancers
Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J
OncoTargets and Therapy 2012, 5:221-229
Published Date: 21 September 2012
Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
Cen P, Amato RJ
OncoTargets and Therapy 2012, 5:217-224
Published Date: 3 April 2012
Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia
Bai J, Guo A, Hong Z, Kuai W
OncoTargets and Therapy 2012, 5:213-219
Published Date: 21 September 2012
Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S
OncoTargets and Therapy 2012, 5:199-211
Published Date: 24 September 2012
Evaluation of therapeutic effect of tumor-targeted therapy
Li XF, Li MD, Shen H, Fang XF, Huang PT, Yuan Y
OncoTargets and Therapy 2012, 5:191-198
Published Date: 17 September 2012
Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial
Yamamoto D, Iwase S, Tsubota Y, Sueoka N, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y
OncoTargets and Therapy 2012, 5:185-189
Published Date: 17 September 2012
Emerging treatment options for patients with recurrent advanced thymic epithelial tumors
Evans TL
OncoTargets and Therapy 2012, 5:177-184
Published Date: 7 September 2012
Expression of transient receptor potential channel 6 in cervical cancer
Wan Q, Zheng A, Liu XJ, Chen YL, Han L
OncoTargets and Therapy 2012, 5:171-176
Published Date: 3 September 2012
Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer
Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K, Willett C
OncoTargets and Therapy 2012, 5:161-170
Published Date: 23 August 2012
Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
Keedy VL
OncoTargets and Therapy 2012, 5:153-160
Published Date: 22 August 2012
Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation
Zhang Y, Wang Y, Du Z, Wang Q, Wu M, Wang X, Wang L, Cao L, Hamid AS, Zhang G
OncoTargets and Therapy 2012, 5:143-152
Published Date: 13 August 2012
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
Fuloria J
OncoTargets and Therapy 2012, 5:133-142
Published Date: 17 August 2012
The role of EGFR-targeting strategies in the treatment of head and neck cancer
Dequanter D, Shahla M, Paulus P, Lothaire PH
OncoTargets and Therapy 2012, 5:127-131
Published Date: 27 July 2012
Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects
Shodeinde AL, Barton BE
OncoTargets and Therapy 2012, 5:119-125
Published Date: 4 July 2012
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
Grüenwald V, Merseburger AS
OncoTargets and Therapy 2012, 5:111-117
Published Date: 18 June 2012
Treatment with transcatheter arterial chemoembolization induces an increase of the L-selectinlow CXCR3+ CD8+ T cell subset in patients with hepatocellular carcinoma
Zheng JS, Sun B, Liu DJ, Yan L, Wang YJ
OncoTargets and Therapy 2012, 5:103-109
Published Date: 8 June 2012
Targeted therapy for esophagogastric cancers: a review
Khattak MA, Martin HL, Karapetis CS
OncoTargets and Therapy 2012, 5:91-102
Published Date: 21 May 2012
Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand
Jia XY, Yu Q, Zhang ZH, Yang XF
OncoTargets and Therapy 2012, 5:85-90
Published Date: 7 May 2012
Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment
Pham PV, Vu NB, Duong TT, Nguyen TT, Truong NH, Phan NLC, Vuong TG, Pham VQ, Nguyen HM, Nguyen KT, Nguyen NT, Nguyen KG, Khat LT, Le DV, Truong KD, Phan NK
OncoTargets and Therapy 2012, 5:77-84
Published Date: 7 May 2012
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
Sato A
OncoTargets and Therapy 2012, 5:67-76
Published Date: 27 April 2012
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
He K, Cui B, Li G, Wang H, Jin K, Teng L
OncoTargets and Therapy 2012, 5:59-65
Published Date: 13 April 2012
Hedgehog pathway as a drug target: Smoothened inhibitors in development
Lin TL, Matsui W
OncoTargets and Therapy 2012, 5:47-58
Published Date: 9 March 2012
Targeted agents for the treatment of metastatic melanoma
Monzon JG, Dancey J
OncoTargets and Therapy 2012, 5:31-46
Published Date: 5 March 2012
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine
Sun W, Modak S
OncoTargets and Therapy 2012, 5:21-29
Published Date: 2 March 2012
Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation
Jacob NK, Cooley JV, Shirai K, Chakravarti A
OncoTargets and Therapy 2012, 5:7-20
Published Date: 15 February 2012
Application of reticulated platelets to transfusion management during autologous stem cell transplantation
Parco S, Vascotto F
OncoTargets and Therapy 2012, 5:1-5
Published Date: 26 January 2012